UK-based pharmaceutical major GlaxoSmithKline (GSK) has announced plans to invest A$60m to expand its manufacturing and drug development activities at its Boronia facility near Melbourne, Australia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The facility is already GSK’s largest in Australia and GSK’s largest sterile manufacturing facility, and the expansion will see the creation of 58 new highly skilled jobs by 2017.
The investment will support the creation of a pilot-scale industrialisation facility for the development of new powder and sterile-liquid pharmaceuticals, whilst the plant will also become accessible as a contract manufacturing facility for local companies.
The Boronia facility’s core function is the company’s ‘blow-fill-seal’ technology, an advanced antiseptic process used to create containers in differing sizes for the delivery of unpreserved sterile products.
Additional equipment, earmarked for purchase as per the investment, will allow GSK to potentially double the plant’s current BFS capacity.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataGSK contributes significantly to the local economy in Victoria, with the company offering employment and manufacturing, as well as spending an average of A$30m per year on local research and development.
Caption: GlaxoSmithKline’s corporate headquarters, located in Brentford, UK. Image: GlaxoSmithKline.
